Altenburger et al. showed that although in vitro-activated CD8+ T cells that were attached to DCs for long periods exhibited persistent TCR signaling during cell division, in lymphoid tissue, DCs and T cells detached before T cell proliferation began. DC-attached T cells were transiently unresponsive, but regained CCR7 response to CCL19/21 over 24-48hrs to reposition F-actin-promoting factor DOCK2 away from the immune synapse and allow T cell detachment, effector gene transcription, and enhanced cytolysis. Prolonged DC–T cell interaction increased PD-1 and LAG3. Detachment favored increased effector function that lasted throughout the memory phase.

Contributed by Paula Hochman

ABSTRACT: The generation of effector CD8(+) T cells (T(EFF)) requires activation of nave CCR7(+) T cells (T(N)) by dendritic cells (DCs) in lymphoid tissue. How T(N)-DC interaction duration and signal integration are controlled remains unclear. In this study, we show that lymphoid stroma-secreted CCR7 ligands limit interaction duration by progressively inducing CD8(+) T cell release from DCs. At late interaction stages, CCR7 ligands relocalize the F-actin regulator DOCK2 away from the DC interface, permitting T cell detachment, proliferation onset, and acquisition of cytotoxicity. Disruption of CCR7 signaling causes prolonged T cell-DC contacts and produces dysfunctional T(EFF) with elevated inhibitory receptors, reduced antimicrobial activity, and impaired recall responses. Stromal chemokines therefore act as critical regulators of T cell priming by DCs, preserving CD8(+) effector function during acute and memory phases.

Author Info: (1) Department of Oncology, Microbiology and Immunology, University of Fribourg, Fribourg, Switzerland. (2) Department of Oncology, Microbiology and Immunology, University of Fribo urg, Fribourg, Switzerland. (3) Department of Biomedicine, University of Basel, Basel, Switzerland. (4) Department of Biology, University of Fribourg, Fribourg, Switzerland. (5) Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy. (6) Department of Oncology, Microbiology and Immunology, University of Fribourg, Fribourg, Switzerland. (7) Institute of Neuropathology, UniversitŠtsklinikum Erlangen, Friedrich-Alexander-UniversitŠt Erlangen-NŸrnberg (FAU), Erlangen, Germany. (8) Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy. (9) Department of Oncology, Microbiology and Immunology, University of Fribourg, Fribourg, Switzerland. (10) Department of Oncology, Microbiology and Immunology, University of Fribourg, Fribourg, Switzerland. (11) Department of Oncology, Microbiology and Immunology, University of Fribourg, Fribourg, Switzerland. (12) Department of Biomedicine, University of Basel, Basel, Switzerland. (13) Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy. Vita-Salute San Raffaele University, Milan, Italy. Experimental Imaging Center, IRCCS San Raffaele Scientific Institute, Milan, Italy. (14) Functional Urology Research Group, Department for BioMedical Research DBMR, University of Bern, Bern, Switzerland. Department of Urology, Inselspital University Hospital, Bern, Switzerland. Urological Diseases Research Center, Boston Children's Hospital, Boston, MA, USA. Harvard Medical School, Department of Surgery, Boston, MA, USA. Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA. (15) Department of Biology, University of Fribourg, Fribourg, Switzerland. (16) Department of Oncology, Microbiology and Immunology, University of Fribourg, Fribourg, Switzerland. (17) Department of Oncology, Microbiology and Immunology, University of Fribourg, Fribourg, Switzerland.